Company intelligence / Profile preview

Cordavis

Dublin, Leinster, Irelandcordavis.com ↗

Ownership: Private
Development stage: Commercial

Overview

Cordavis, a wholly owned subsidiary of CVS Health, was founded in 2023 to co-manufacture and commercialize FDA-approved biosimilar products for the U.S. market. Its first product is Hyrimoz® (adalimumab-adaz), a biosimilar to Humira®, launched in Q1 2024 at over 80% lower list price than Humira. The company aims to expand access and affordability of high-quality biosimilars through direct partnerships with manufacturers and robust quality oversight[1][2][3][4].

Therapeutic areas: GastroenterologyDermatologyRheumatologyImmunology
Modalities: Biosimilars (biologic drugs highly similar to reference biologics)
Industry: Biotech

Drug pipeline

1 asset

adalimumab-adaz

Commercial

Indications: Rheumatoid arthritis, Juvenile idiopathic arthritis, Psoriatic arthritis, Ankylosing spondylitis, Crohn's disease, Ulcerative colitis, Plaque psoriasis, Hidradenitis suppurativa

Partnerships

Sandoz [co-manufacturing/commercialization partner for Hyrimoz® biosimilar][2][3]

Beyond the preview

Go deeper on Cordavis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cordavis.

Explore the full profile